美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

299.94

-5.8000-1.90%

盘后：299.940.00000.00%17:04 EDT

成交量：47.30万

成交额：1.43亿

市值：355.88亿

市盈率：-80.99

高：306.58

开：302.89

低：298.46

收：305.74

数据加载中...

总览公司新闻公告

百济神州百悦泽®片剂获欧洲药品管理局人用药品委员会积极意见

百济神州6月24日成交额为1.20亿美元

"长守护悦新生"2025淋巴瘤患者关爱活动举行

创新药大牛市继续，最受益也是中国最强的创新药龙头，没有之一！

价值事务所

港股创新药ETF涨2.25%，成交额23.73亿元

百济神州：生物科技出海明星 2025年迎来蝶变

西南证券股份有...

百济神州6月23日成交额为1.16亿美元

【医药生物】创新药审评再次加速，创新药产业链主线持续明确——医药生物行业跨市场周报（20250622）（王明瑞）

光大证券研究

百济神州涨逾3% 百赫安于中国正式投入临床使用

生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团

百济神州宣布百赫安®在中国正式投入临床使用

2025全球制药50强榜单最新出炉！百济神州首次上榜

MedTrend医趋势

6月20日百济神州-UAH溢价达79.85%，位居AH股溢价率第52位

百济神州6月18日成交额为5867.21万美元

这家跨国药企总裁将离职，或加盟百济神州！

维立志博累亏超7亿：百济神州今年终止协议，短期偿债压力偏大

IPO前夕股东折价“出逃”！百济神州“断供”后，维立志博“零收入”冲港｜创新药观察

【医药生物】AI技术落地与产品创新呈现加速态势，建议关注AI医疗相关标的——医药生物行业跨市场周报（20250615）（王明瑞）

光大证券研究

百济神州6月16日成交额为8655.04万美元

百济神州：2025年第一季度公司营业收入达80.5亿元，同比增长50.2%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news?page=7"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":299.94,"timestamp":1753905600000,"preClose":305.74,"halted":0,"volume":473024,"hourTrading":{"tag":"盘后","latestPrice":299.94,"preClose":299.94,"latestTime":"17:04 EDT","volume":1443,"amount":433016.27,"timestamp":1753909481311},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"未开盘","change":-5.8,"latestTime":"07-30 16:00:00 EDT","open":302.89,"high":306.58,"low":298.46,"amount":142842075.17312,"amplitude":0.026559,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753948800000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":305.74,"preHourTrading":{"tag":"盘前","latestPrice":302.03,"preClose":305.74,"latestTime":"09:26 EDT","volume":20145,"amount":6149166.5685,"timestamp":1753882010837},"postHourTrading":{"tag":"盘后","latestPrice":299.94,"preClose":299.94,"latestTime":"17:04 EDT","volume":1443,"amount":433016.27,"timestamp":1753909481311},"volumeRatio":1.182299,"impliedVol":0.4534,"impliedVolPercentile":0.7133},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.182299,"shares":118650120,"dividePrice":0,"high":306.58,"amplitude":0.026559,"preClose":305.74,"low":298.46,"week52Low":155.75,"pbRate":"10.17","psRate":"8.52","week52High":308.87,"institutionHeld":0,"latestPrice":299.94,"eps":-3.70325,"divideRate":0,"volume":473024,"delay":0,"ttmEps":-3.70325,"open":302.89,"prevYearClose":184.71,"prevWeekClose":291.47,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":294.83,"twentyDayClose":245.16,"sixtyDayClose":255.77,"earningDate":1756483200000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546421137","title":"百济神州百悦泽®片剂获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2546421137","media":"百济神州","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546421137?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 18:06","pubTimestamp":1750845997,"startTime":"0","endTime":"0","summary":"美国加州圣卡洛斯——百济神州有限公司是一家全球肿瘤治疗创新公司，今日宣布欧洲药品管理局人用药品委员会发布积极意见，推荐批准百悦泽新的薄膜包衣片剂剂型用于所有已获批适应症。欧盟委员会将对CHMP的积极意见进行审评，如通过批准，片剂剂型在欧盟和欧洲经济区国家挪威和冰岛上市。本新闻稿中的所有信息仅及于新闻稿发布之日，除非法律要求，百济神州并无责任更新该等信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625183749a4bd317c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625183749a4bd317c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK0239","ONC"],"gpt_icon":0},{"id":"2546726445","title":"百济神州6月24日成交额为1.20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546726445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546726445?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 12:34","pubTimestamp":1750826076,"startTime":"0","endTime":"0","summary":"美东时间2025年6月24日，百济神州成交额为1.20亿美元，成交额较昨日增加3.37%，当日成交量为45.06万股。百济神州于2025年6月24日涨3.61%，报266.8美元，该股过去5个交易日涨0.9%，年初至今涨44.44%，过去60日涨1.6%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625123445a71c564b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625123445a71c564b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2546232068","title":"\"长守护 悦新生\"2025淋巴瘤患者关爱活动举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2546232068","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546232068?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 21:45","pubTimestamp":1750772700,"startTime":"0","endTime":"0","summary":"\"长守护 悦新生\"2025淋巴瘤患者关爱活动  淋巴瘤是我国最常见的血液系统肿瘤之一，具有分型复杂、起病隐匿、早期诊断难度大、病程长且易复发等特点，为患者及其家庭带来了较为沉重的疾病负担。淋巴瘤患者故事纪录片《英雄》也在活动现场首映。影片讲述了三位不同年龄、不同职业的淋巴瘤患者积极治疗、热爱生活的真实故事，激励更多患友要做生活中的英雄。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4717198_ZH17198_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0307460666.USD","688235","LU0588546209.SGD","BK4139","BK4526","BK1500","ONC","BK1588","LU2328871848.SGD","BK1583","BK1161","06160","BK0239","LU1969619763.USD"],"gpt_icon":0},{"id":"2545805762","title":"创新药大牛市继续，最受益也是中国最强的创新药龙头，没有之一！","url":"https://stock-news.laohu8.com/highlight/detail?id=2545805762","media":"价值事务所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545805762?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 20:58","pubTimestamp":1750769912,"startTime":"0","endTime":"0","summary":"连当代创新药的发源地欧美都开始争相关注并报道咱们国内的创新药突破，这其实就已经很能够说明一些问题了。这不仅是百济自身的转折点，其实也是国内创新药行业从 “资本驱动” 迈向 “价值创造” 的重要信号。对大多数 Biotech 而言，这样的路径既是范本，也是九死一生的缩影。创新药的上岸之路，从来都是烧钱换时间的残酷游戏。如今国内创新药崛起之势不","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624210233a4bb8bd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624210233a4bb8bd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4614","ONC","06160","YANG","BK4526","688235","BK4139"],"gpt_icon":0},{"id":"2545523545","title":"港股创新药ETF涨2.25%，成交额23.73亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545523545","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545523545?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 15:04","pubTimestamp":1750748662,"startTime":"0","endTime":"0","summary":"6月24日，港股创新药ETF收盘涨2.25%，成交额23.73亿元。港股创新药ETF成立于2024年1月3日，基金全称为银华国证港股通创新药交易型开放式指数证券投资基金，基金简称为港股创新药ETF。回顾2024年12月31日，港股创新药ETF份额为3.95亿份，规模为3.78亿元。流动性方面，截止6月24日，港股创新药ETF近20个交易日累计成交金额384.34亿元，日均成交金额19.22亿元；今年以来，113个交易日，累计成交金额793.25亿元，日均成交金额7.02亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624222703a4bbaa2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624222703a4bbaa2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4139"],"gpt_icon":0},{"id":"2545474477","title":"百济神州：生物科技出海明星 2025年迎来蝶变","url":"https://stock-news.laohu8.com/highlight/detail?id=2545474477","media":"西南证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545474477?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 13:40","pubTimestamp":1750743628,"startTime":"0","endTime":"0","summary":"2）在研Bcl-2i 和BTK CDAC 于2025 年迎来多项催化事件，未来依托泽布替尼全球商业化渠道，拓宽加深血液瘤市场覆盖。百济神州国内药企出海标杆，预计公司25 年有望盈利。百济神州于2010 年创立，是美股+H 股+A 股三地上市的创新药企业。公司于2025 年JPM 大会宣布当年目标实现营运利润为正。2025 年公司Bcl2i Sonrotoclax 有望完成首个注册临床研究。PanKRASi、EGFR CDAC、CDK2i、多项ADC 有望于2025 年下半年首次读出概念验证数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624134036978c50ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624134036978c50ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","159837","ONC","BK0239","06160"],"gpt_icon":0},{"id":"2545792114","title":"百济神州6月23日成交额为1.16亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545792114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545792114?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 12:33","pubTimestamp":1750739600,"startTime":"0","endTime":"0","summary":"美东时间2025年6月23日，百济神州成交额为1.16亿美元，成交额较昨日增加103.45%，当日成交量为45.07万股。百济神州于2025年6月23日涨4.22%，报257.51美元，该股过去5个交易日跌4.5%，年初至今涨39.41%，过去60日涨2.63%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624123324a71a8aed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624123324a71a8aed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2545142588","title":"【医药生物】创新药审评再次加速，创新药产业链主线持续明确——医药生物行业跨市场周报（20250622）（王明瑞）","url":"https://stock-news.laohu8.com/highlight/detail?id=2545142588","media":"光大证券研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545142588?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 07:02","pubTimestamp":1750719778,"startTime":"0","endTime":"0","summary":"非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。H股恒生医疗健康指数上周收跌7.72%，跑输恒生国企指数6.24pp。众生药业的RAY1225、恒瑞医药的HRS-1893正在进行三期临床；翰森制药的HS-10370、三生制药的SSGJ-612正在进行一期临床。本周观点：创新药审评再次加速，创新药产业链主线持续明确2025年6月16日，国家药监局综合司公开征求《关于优化创新药临床试验审评审批有关事项的公告》意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624070629a71a09c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624070629a71a09c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1593","03692","06160","ONC","BK1583","01530","06978","600276"],"gpt_icon":0},{"id":"2545445611","title":"百济神州涨逾3% 百赫安 于中国正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2545445611","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545445611?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 22:50","pubTimestamp":1750690206,"startTime":"0","endTime":"0","summary":"周一，百济神州(ONC.US)涨逾3%，报255.81美元。消息面上，百济神州6月23日宣布双特异性HER2抑制剂百赫安(注射用泽尼达妥单抗)在中国正式供应，并同步在全国多家医疗机构投入临床使用。作为中国首个且目前唯一1获批用于靶向治疗HER2高表达胆道癌的双特异性抗体，首批药物将迅速在全国百余个城市的医院和药房落地，惠及胆道癌(BTC)患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623233944a4b96864&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623233944a4b96864&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2545187754","title":"生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2545187754","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545187754?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 18:07","pubTimestamp":1750673278,"startTime":"0","endTime":"0","summary":"艾伯维、阿斯利康等多个制药巨头已通过合作/收购布局体内CAR-T赛道。石药集团自主研发的mRNA-LNP的自体CAR-T疗法进入临床，体内CAR-T的布局亦可期待。全球自体CAR-T细胞疗法全球销售额2024年合计超45亿美金，制造过程繁琐、可及性低和价格昂贵的缺点限制其应用。实现体内CAR-T疗法的核心挑战，在于如何将CAR构建体精准、高效且安全地递送至目标T细胞。慢病毒载体可将CAR基因永久整合到宿主T细胞的基因组中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","01801","BK4139","LU2488822045.USD","BK4526","02105","09688","BK4230","BK4022","CAR","BK4585","ZLAB","BK4588","ONC","09926","688235","06160","BK4548","01672","BK4531"],"gpt_icon":0},{"id":"2545413240","title":"百济神州宣布百赫安®在中国正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2545413240","media":"百济神州","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545413240?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 18:01","pubTimestamp":1750672903,"startTime":"0","endTime":"0","summary":"中国北京——百济神州有限公司是一家全球肿瘤治疗创新公司，今日宣布双特异性HER2抑制剂百赫安在中国正式供应，并同步在全国多家医疗机构投入临床使用。因此，BTC患者亟需新的临床治疗选择。目前，BTC全球发病率呈现上升趋势，以亚洲国家为常见14。本新闻稿中的所有信息仅及于新闻稿发布之日，除非法律要求，百济神州并无责任更新该等信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623183229a718933b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623183229a718933b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","ONC","BK0239"],"gpt_icon":0},{"id":"2545928104","title":"2025全球制药50强榜单最新出炉！百济神州首次上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2545928104","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545928104?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 10:55","pubTimestamp":1750474553,"startTime":"0","endTime":"0","summary":"6月20日晚，美国《制药经理人》杂志重磅“2025 全球制药企业50强”榜单发布，时间对比以往稍晚了一些。其2024年处方药收入增加超过70亿美元，总计509.5亿美元，增幅16.3%。其免疫治疗重磅药Imfinzi在2025年第一季度因需求加速和新适应症获批，销售额增长11.6%。02中国药企全面崛起从中国药企来看，是上榜最多的一次，有6家企业上榜，其中百济神州、华东医药、是新晋上榜，石药集团再次回归。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621105928a715857a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621105928a715857a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139","688235","06160"],"gpt_icon":0},{"id":"2544288142","title":"6月20日百济神州-UAH溢价达79.85%，位居AH股溢价率第52位","url":"https://stock-news.laohu8.com/highlight/detail?id=2544288142","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544288142?lang=zh_cn&edition=fundamental","pubTime":"2025-06-20 16:39","pubTimestamp":1750408774,"startTime":"0","endTime":"0","summary":"6月20日，上证指数跌0.07%，收报3359.9点，恒生指数涨1.26%，收报23530.48点。当日收盘，百济神州-UA股报244.89元，跌幅0.66%，H股报148.8港元，上涨0.74%。资料显示，百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620165757a7142a0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620165757a7142a0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK4526","ONC","BK4139"],"gpt_icon":0},{"id":"2544139125","title":"百济神州6月18日成交额为5867.21万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544139125","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544139125?lang=zh_cn&edition=fundamental","pubTime":"2025-06-19 12:15","pubTimestamp":1750306526,"startTime":"0","endTime":"0","summary":"美东时间2025年6月18日，百济神州成交额为5867.21万美元，成交额较昨日减少45.50%，当日成交量为23.04万股。百济神州于2025年6月18日跌0.52%，报252.78美元，该股过去5个交易日跌3.67%，年初至今涨36.85%，过去60日跌0.17%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619121527a711c1d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619121527a711c1d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2544069136","title":"这家跨国药企总裁将离职，或加盟百济神州！","url":"https://stock-news.laohu8.com/highlight/detail?id=2544069136","media":"制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544069136?lang=zh_cn&edition=fundamental","pubTime":"2025-06-19 11:56","pubTimestamp":1750305388,"startTime":"0","endTime":"0","summary":"近日，据多家媒体报道，武田制药全球高级副总裁、武田中国总裁单国洪即将离职，其下一站很有可能加入百济神州。至于单国洪下一站或将加盟的百济神州，近年来也在全球生物医药领域发展势头迅猛。目前，武田中国已宣布消化事业部负责人刘燕将于2025年7月1日起暂时代理总裁一职，全面接管武田中国事业部的战略和运营管理工作，而百济神州方面尚未就单国洪加盟一事做出回应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506191158189785f2d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506191158189785f2d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1500","688235","06160","LU2328871848.SGD","BK1583","LU1969619763.USD","ONC","BK1161","LU0588546209.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2544138489","title":"维立志博累亏超7亿：百济神州今年终止协议，短期偿债压力偏大","url":"https://stock-news.laohu8.com/highlight/detail?id=2544138489","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544138489?lang=zh_cn&edition=fundamental","pubTime":"2025-06-19 08:20","pubTimestamp":1750292400,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2025-06-19/doc-infaqerx4105959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1500","LU2328871848.SGD","LU0307460666.USD","BK4139","BK1161","09887","BK0239","688235","BK4526","LU0588546209.SGD","LU1969619763.USD","BK1588","06160","ONC","BK1583"],"gpt_icon":0},{"id":"2544594029","title":"IPO前夕股东折价“出逃”！百济神州“断供”后，维立志博“零收入”冲港｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2544594029","media":"华夏时报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544594029?lang=zh_cn&edition=fundamental","pubTime":"2025-06-18 14:34","pubTimestamp":1750228440,"startTime":"0","endTime":"0","summary":"除化疗外，全球范围内尚无专门用于治疗晚期肺外神经内分泌癌的获批药物。百济神州“断供”斩断唯一收入链与众多处于研发驱动期的创新药企相似，维立志博尚未实现产品商业化落地，持续投入的高额研发成本正不断消耗资金储备。2022年至2025年一季度，维立志博的客户名单上仅有百济神州这根“独苗”。至此，维立志博失去了唯一的收入来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-06-18/doc-infannhi5773839.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-06-18/doc-infannhi5773839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","06160","LU0307460666.USD","LU0588546209.SGD","BK1500","BK1588","LU1969619763.USD","LU2328871848.SGD","159992","BK0239","BK4139","BK4526","ONC","688235","09887","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2544991946","title":"【医药生物】AI技术落地与产品创新呈现加速态势，建议关注AI医疗相关标的——医药生物行业跨市场周报（20250615）（王明瑞）","url":"https://stock-news.laohu8.com/highlight/detail?id=2544991946","media":"光大证券研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544991946?lang=zh_cn&edition=fundamental","pubTime":"2025-06-18 07:02","pubTimestamp":1750201320,"startTime":"0","endTime":"0","summary":"光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相关人员为光大证券的客户。预期未来将有更多的中国药企通过AI平台授权参与全球创新，推动产业链向技术驱动转型。AI制药有望成为创新药国际化的重要引擎。如因侵权行为给光大证券造成任何直接或间接的损失，光大证券保留追究一切法律责任的权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618075253a70f46ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618075253a70f46ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","IE00BZ08YT58.USD","LU1152091168.USD","LU1226288170.HKD","IE0008368742.USD","LU1008478684.HKD","LU1152091754.HKD","ONC","LU0067412154.USD","LU1226287529.USD","IE0008369823.USD","LU0326950275.SGD","BK1191","LU1951186391.HKD","600079","BK1515","LU0501845795.SGD","BK1521","600276","IE00BZ08YS42.EUR","LU1226287792.SGD","LU0880133367.SGD","IE00B031HY20.USD","09926","SG9999004220.SGD","01093","LU1960683339.HKD","IE00B543WZ88.USD","LU1226287875.USD","IE00B5MMRT66.SGD","LU0140636845.USD","LU1226288253.USD","IE00BZ08YR35.GBP","LU0072913022.USD","LU1807302812.USD","LU1993786604.SGD"],"gpt_icon":1},{"id":"2544934966","title":"百济神州6月16日成交额为8655.04万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544934966","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544934966?lang=zh_cn&edition=fundamental","pubTime":"2025-06-17 12:24","pubTimestamp":1750134259,"startTime":"0","endTime":"0","summary":"美东时间2025年6月16日，百济神州成交额为8655.04万美元，成交额较昨日减少18.48%，当日成交量为32.67万股。百济神州于2025年6月16日跌1.93%，报264.42美元，该股过去5个交易日涨0.24%，年初至今涨43.15%，过去60日涨0.7%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617122425a70d7981&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617122425a70d7981&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4139"],"gpt_icon":0},{"id":"2544793964","title":"百济神州：2025年第一季度公司营业收入达80.5亿元，同比增长50.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544793964","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544793964?lang=zh_cn&edition=fundamental","pubTime":"2025-06-17 11:32","pubTimestamp":1750131120,"startTime":"0","endTime":"0","summary":"来源：Gangtise投研\n　　百济神州2025年第一季度财报显示，公司营业收入达80.5亿元，同比增长50.2%，主要得益于产品收入的增长。经调整后，公司实现营业利润11.71亿元，净利润8.85亿元。研发投入为34.74亿元，占营业收入的比例为43.16%。公司总资产为421亿元，归属于上市公司股东的所有者权益为252亿元。前十大股东中，安进持股比例为17.55%，为最大股东。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郝欣煜","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-06-17/doc-infakazn8790286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","06160","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":7,"totalSize":164,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-29","current":-89.058804,"percent":0.017123,"low":-89.808695,"twenty":-49.066613,"median":-39.846019,"eighty":-23.213907,"high":-19.234246,"avg":-41.413887,"sd":19.655313,"marketCap":34943646841},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-07-29","current":-89.058804,"twenty":-49.066613,"median":-39.846019,"eighty":-23.213907,"marketCap":34943646841}],"updateTime":1753934667684}}}